Information Related to Clinical Trials
TaiRx’s novel anti-cancer drug CVM-1118 is currently in Phase II clinical program.
If you would like to learn more information regarding the clinical trials, please contact the nearest clinical trial center.
News
TaiRx’s New Drug CVM-1118 Granted Orphan Drug Designation for Pancreatic Neuroendocrine Tumors (PNETs), Securing Seven Years of Market Exclusivity in the U.S.
2025/1/31 TaiRx’s orally administered anticancer drug, CVM-1118 (Foslinanib), was [...]
Company Announcement for Zelnite®
2024/7/17 TaiRx, Inc. hereby declares that Zelnite® is the only selenium injection product [...]
TaiRx‘s injectable product, Zelnite®, has been approved by TFDA to add high dosage and change drug labeling
2024/5/9 In 2018, TaiRx received approval from the Food and Drug Administration (TFDA) [...]